Patents by Inventor Trevor N. Collingwood

Trevor N. Collingwood has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220089659
    Abstract: Constructs comprising Argonautes and neighboring genes are disclosed for use in gene editing. Disclosed are also compositions and methods utilizing these Argonautes and neighboring genes. Also disclosed are the methods of making and using the Argonautes and neighboring genes in treating various diseases, conditions, and cancer.
    Type: Application
    Filed: September 1, 2021
    Publication date: March 24, 2022
    Applicants: The Board of Trustees of the Leland Stanford Junior University, Intima Bioscience, Inc.
    Inventors: Lei S. Qi, Modassir Choudhry, Xueqiu Lin, Trevor N. Collingwood, Thomas Henley, Benjamin Klapholz, Tilmann Buerckstuemmer, Sejla Salic
  • Patent number: 9062338
    Abstract: The present invention provides non-human mammalian cell lines that are deficient in CMP-Neu5Ac hydroxylase (Cmah) and/or glycoprotein alpha-1,3-galactosyltransferase (Ggta1). Also provided are methods for using the cells disclosed herein for producing recombinant proteins with human-like patterns of glycosylation.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: June 23, 2015
    Assignee: SIGMA-ALDRICH CO. LLC
    Inventors: Nan Lin, Henry J. George, Joaquina Mascarenhas, Trevor N. Collingwood, Kevin J. Kayser, Katherine Achtien
  • Publication number: 20150152463
    Abstract: The present invention provides non-human mammalian cell lines that are deficient in CMP-Neu5Ac hydroxylase (Cmah) and/or glycoprotein alpha-1,3-galactosyltransferase (Ggta1). Also provided are methods for using the cells disclosed herein for producing recombinant proteins with human-like patterns of glycosylation.
    Type: Application
    Filed: January 30, 2015
    Publication date: June 4, 2015
    Applicant: SIGMA-ALDRICH CO. LLC
    Inventors: Nan Lin, Henry J. George, Joaquina Mascarenhas, Trevor N. Collingwood, Kevin J. Kayser, Katherine Achtien
  • Patent number: 8980583
    Abstract: The present invention provides non-human mammalian cell lines that are deficient in CMP-Neu5Ac hydroxylase (Cmah) and/or glycoprotein alpha-1,3-galactosyltransferase (Ggta1). Also provided are methods for using the cells disclosed herein for producing recombinant proteins with human-like patterns of glycosylation.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: March 17, 2015
    Assignee: Sigma-Aldrich Co. LLC
    Inventors: Nan Lin, Henry J. George, Joaquina Mascarenhas, Trevor N. Collingwood, Kevin J. Kayser, Katherine Achtien
  • Publication number: 20130004992
    Abstract: The present invention provides non-human mammalian cell lines that are deficient in CMP-Neu5Ac hydroxylase (Cmah) and/or glycoprotein alpha-1,3-galactosyltransferase (Ggta1). Also provided are methods for using the cells disclosed herein for producing recombinant proteins with human-like patterns of glycosylation.
    Type: Application
    Filed: June 29, 2012
    Publication date: January 3, 2013
    Applicant: SIGMA-ALDRICH CO. LLC
    Inventors: Nan Lin, Henry J. George, Joaquina Mascarenhas, Trevor N. Collingwood, Kevin J. Kayser, Katherine Achtien
  • Publication number: 20110306559
    Abstract: Compositions and methods for the treatment of neuropathic pain are provided. Compositions of the invention may comprise proteins with a zinc-finger domain fused to a regulatory domain that is capable of either activating or repressing the expression of a target gene involved in neuropathic pain. Alternatively, compositions of the invention may comprise a nucleic acid sequence encoding a protein of the invention, which nucleic acid sequence may optionally be provided as a plasmid or within a virus or other vector for delivery to a target cell or tissue. Methods of treating neuropathic pain involving treatment of subject with the compositions of the invention are also provided. Exemplary target genes for the treatment of neuropathic pain include VR1, NaV1.8, and TrkA.
    Type: Application
    Filed: December 23, 2009
    Publication date: December 15, 2011
    Applicant: SANGAMO BIOSCIENCES, INC.
    Inventors: John R.M. Forsayeth, Raymond A. Chavez, Trevor N. Collingwood